Compare
MannKind Corp vs Ardelyx, Inc. vs Evolus, Inc. vs Ironwood Pharmaceuticals Inc
| Latest fiscal year | MannKind Corp MNKD | Ardelyx, Inc. ARDX | Evolus, Inc. EOLS | Ironwood Pharmaceuticals Inc IRWD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $348.97M | $407.32M | $297.18M | $296.15M |
| Revenue growth (YoY) | +22.2% | +22.1% | +11.6% | -15.7% |
| Gross margin | 92.3% (computed) | 90.3% (computed) | 66.3% | n/a |
| Operating margin | 11.1% | -10.1% | -11.0% | 33.3% |
| Net margin | 1.7% | -15.1% | -17.4% | 8.1% |
| Net income | $5.86M | -$61.60M | -$51.64M | $24.02M |
| EPS (Diluted) | $0.02 | -$0.26 | -$0.80 | $0.15 |
| Operating cash flow | $18.25M | -$42.48M | -$42.27M | $127.04M |
| Free cash flow | $13.69M | -$43.98M | -$45.71M | $127.01M |
| Cash & equivalents | $74.88M | $68.00M | $53.83M | $215.46M |
| Total assets | $792.18M | $501.60M | $225.87M | $396.90M |
| Total liabilities | $843.20M | $334.65M | $248.97M | n/a |
| Shareholders' equity | -$51.02M | $166.95M | -$23.11M | -$261.83M |
| Return on year-end equity | n/a | -36.9% | n/a | n/a |
| Shares outstanding | 307.83M | 244.35M | 65.01M | 163.06M |
Revenue, most recent five fiscal years
| Fiscal year | MannKind Corp | Ardelyx, Inc. | Evolus, Inc. | Ironwood Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | $348.97M Ended 2025-12-31 | $407.32M Ended 2025-12-31 | $297.18M Ended 2025-12-31 | $296.15M Ended 2025-12-31 |
| 1 year earlier | $285.50M Ended 2024-12-31 | $333.62M Ended 2024-12-31 | $266.27M Ended 2024-12-31 | $351.41M Ended 2024-12-31 |
| 2 years earlier | $198.96M Ended 2023-12-31 | $124.46M Ended 2023-12-31 | $202.09M Ended 2023-12-31 | $442.74M Ended 2023-12-31 |
| 3 years earlier | $99.77M Ended 2022-12-31 | $52.16M Ended 2022-12-31 | $148.62M Ended 2022-12-31 | $410.60M Ended 2022-12-31 |
| 4 years earlier | $75.44M Ended 2021-12-31 | $10.10M Ended 2021-12-31 | $99.67M Ended 2021-12-31 | $413.75M Ended 2021-12-31 |